Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease

European Journal of Neuroscience - Tập 15 Số 1 - Trang 120-132 - 2002
Julia Fuchs1, Malin Andersson1, Christian Winkler2,1, Deniz Kirik1, Nils Wierup1, M. Angela Cenci1
1Department of Physiological Sciences, Lund University, Wallenberg Neuroscience Centre, Neurobiology Division, BMC A11, S-221 84 Lund, Sweden
2Department of Neurology, Hannover Medical School, Hannover, Germany

Tóm tắt

AbstractIn an attempt to define clinically relevant models of akinesia and dyskinesia in 6‐hydroxydopamine (6‐OHDA)‐lesioned rats, we have examined the effects of drugs with high (l‐DOPA) vs. low (bromocriptine) dyskinesiogenic potential in Parkinson's disease on three types of motor performance, namely: (i) abnormal involuntary movements (AIMs) (ii) rotational behaviour, and (iii) spontaneous forelimb use (cylinder test). Rats with unilateral 6‐OHDA lesions received single daily i.p. injections of l‐DOPA or bromocriptine at therapeutic doses. During 3 weeks of treatment, l‐DOPA but not bromocriptine induced increasingly severe AIMs affecting the limb, trunk and orofacial region. Rotational behaviour was induced to a much higher extent by bromocriptine than l‐DOPA. In the cylinder test, the two drugs initially improved the performance of the parkinsonian limb to a similar extent. However, l‐DOPA‐treated animals showed declining levels of performance in this test because the drug‐induced AIMs interfered with physiological limb use, and gradually replaced all normal motor activities. l‐DOPA‐induced axial, limb and orolingual AIM scores were significantly reduced by the acute administration of compounds that have antidyskinetic efficacy in parkinsonian patients and/or nonhuman primates (−91%, yohimbine 10 mg/kg; −19%, naloxone 4–8 mg/kg; −37%, 5‐methoxy 5‐N,N‐dimethyl‐tryptamine 2 mg/kg; −30%, clozapine 8 mg/kg; −50%, amantadine 40 mg/kg). l‐DOPA‐induced rotation was, however, not affected. The present results demonstrate that 6‐OHDA‐lesioned rats do exhibit motor deficits that share essential functional similarities with parkinsonian akinesia or dyskinesia. Such deficits can be quantified using novel and relatively simple testing procedures, whereas rotometry cannot discriminate between dyskinetic and antiakinetic effects of antiparkinsonian treatments.

Từ khóa


Tài liệu tham khảo

10.1006/nbdi.1999.0259

10.1016/0006-8993(86)90783-3

10.1212/WNL.43.8.1551

10.1038/35086062

10.1002/mds.870130507

Brotchie J.M., 1998, Advances in Neurology, Dystonia 3, 41

10.1016/0006-8993(91)91399-L

10.1016/0024-3205(91)90526-H

10.1046/j.1460-9568.1998.00285.x

10.1016/0091-3057(95)02280-5

10.1006/exnr.1998.6887

10.1016/0006-8993(73)90302-8

10.1111/j.1460-9568.1996.tb01220.x

10.1111/j.1469-185X.1992.tb01191.x

10.1212/WNL.48.3.658

10.1097/00002826-199310000-00004

10.1212/WNL.52.4.771

10.1007/s002109900167

10.1002/1531-8257(199905)14:3<448::AID-MDS1010>3.0.CO;2-0

10.1006/exnr.1998.6819

10.1002/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7

10.1016/0301-0082(94)90055-8

10.1006/nbdi.2000.0372

10.1006/exnr.1998.6848

10.1523/JNEUROSCI.20-12-04686.2000

10.1126/science.290.5492.767

10.1093/brain/123.7.1365

10.1016/0306-4522(95)00571-4

10.1136/jnnp.44.11.1020

10.1016/0361-9230(96)00027-5

10.1097/00001756-199709290-00036

10.1002/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I

10.1523/JNEUROSCI.18-11-04271.1998

10.1073/pnas.94.25.14083

10.1002/1531-8257(200003)15:2<336::AID-MDS1023>3.0.CO;2-R

10.1016/0014-2999(73)90132-5

10.1016/0301-0082(91)90032-V

10.1016/0165-0270(91)90048-5

10.1016/0014-2999(90)94062-3

10.1212/WNL.40.2.340

10.1523/JNEUROSCI.15-05-03863.1995

10.1002/mds.870130207

10.1002/ana.410420508

10.1002/mds.1143

Rascol O., 1999, Clinical pharmacology of levodopa‐induced dyskinesia in parkinsonian patients, Adv. Neurol., 80, 485

10.1056/NEJM200005183422004

10.1136/jnnp.42.2.143

10.1016/S1385-299X(97)00034-2

10.1176/ajp.143.1.118a

10.1016/0306-4522(94)90605-X

10.1017/S0140525X00037481

10.1016/s0028-3908(00)00005-8

10.1007/978-1-59259-691-1_8

10.1016/S0301-0082(96)00040-8

10.1038/350614a0

10.1016/0014-2999(92)90561-H

10.1097/00002826-200003000-00004

10.1016/s0028-3908(99)00076-3

10.1001/archneur.1982.00510140054014

10.1007/s002130050322

10.1016/0014-2999(68)90164-7

10.1016/0306-039X(76)90016-7

10.1016/0006-8993(70)90187-3

Thông tin
Thông tin xuất bản

European Journal of Neuroscience

Tập 15 Số 1

120-132

Thông tin tác giả